The report by Tully e t (17) unequivocally demonstrates t h a t when wr procedures for sample collection, processing, and storage (26,27) a r e followed and when our methods for t h e analysis of sera by i s o e l e c t r i c focusing (IEF) a r e adhered t o (19.24.26) without s i g n i f i c a n t variation (24), then t h e c y s t i c f i b r o s i s protein (CFP) is readily detected i n a l l c y s t i c f i b r o s i s (CF) genotypes a t a frequency close t o t h a t reported by our grcup previously (26). In addition, t h e r e s u l t s of Tully e t a l . (17) a l s o confirm our finding t h a t there e x i s t s a s m l l ( l e s s thansubpopulation of individuals diagnosed a s having CF who a r e CFP negative. This population of "CF patients" may represent e i t h e r ( a ) individuals who have mild symptans r e l a t i v e t o a l l m j o r problems associated with the disease; (b) individuals who do not have CF and who bere misbiawosed prinarily due t o heavy reliance by sane physicians on "sweat t e s t " r e s u l t s , which may be called positive when only borderline positive o r which may not be accurate a t all [depending on t h e method employed t o measure t h e e l e c t r o l y t e s i n sweat, f a l s e positive r e s u l t s may be a s high a s 5% and f a l s e negative r e s u l t s a s high a s 15% ( 5 ) l ; o r ( c ) individuals who have CF but who present a d i f f e r e n t propensity f r m CFP-positive patients for the development of a c e r t a i n aspect of the disease. For example, hypothetically it m y be found t h a t CFP-negative patients do not present extensive pancreatic insufficiency o r may have m r e extensive pulmonary involvement.
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If e i t h e r (a) o r ( c ) is c o r r e c t , it c e r t a i n l y m u l d appear t h a t CF is a syndrome which involves a t l e a s t tho potentially definable disease e n t i t i e s .
I f CFP-positive and -negative CF patients a r e carefully canpared using multiple c r i t e r i a involving both t h e prinary and secondary c l i n i c a l complications normally observed i n patients with CF ( a ) , it mi&t be w s s i b l e t o c l e a r l v delineate both tvoes. and t h i s could add t o our understanding of the r o l d of CFP i n t h e icseise.
Such documentation might a l s o be helpful t o t h e physician i n determining the best therapeutic regimen t o follow, and m y ensure more e f f e c t i v e treatment of the patients.
The present c o n f i m t i o n by Tully e t (17) of o w findin-regarding CFP p o s i t i v i t y i n both c a r r i e r s and patients, and the previous confirmation by Scholey e t a l . (11) concerning the detection of CFP i n CF p a t i e n t s using our electrofocusing methods (19, 26) , provide strong evidence t h a t cur r e s u l t s a r e reproducible and accurate and a r e not "suspect" a s Stated by Thmas, Merritt and Hodes (16) . Indeed. the f a c t t h a t CFP has nou been confirmed as a valid m r k e r for t h e CF gene suggests t h a t the i n a b i l i t y of some investigat o r s ( f o r example, references 14 and 16) t o confirm our findings m s t be r e l a t e d t o t h e i r f a i l u r e t o adhere t o the guidelines proposed previmsly (19.24.26.27 ).
Alternativelv. we rmv have f a i l e d t o em~hasize sane wt of the'technique t h a t is c r u c i i i t o reproducing o w r e s u l t s , and t h i s miy have led sane (but not other) investigators t o believe t h a t t h i s part could be changed without jeopardizing the successful use of the method.
Before discussing t h e potential of CFP a s a screening t e s t for detecting c a r r i e r s of CF, i t m y be i n s t r u c t i v e t o other investigators hho e l e c t t o use our method CFP-positive were not employed [ a t l e a s t CFP bas never found i n any samples reported i n reference 7 , although, a s s t a t e d i n an e a r l i e r a b s t r a c t (151, sane "apparently CFP-positive" specitu?ns were a t hand]; and (b) a colored f i l t e r xas not used t o examine the gels. Instead, changes were i n s t i t u t e d t o "improve" our method f o r CFP detection. While these changes may have led t o b e t t e r resolution, c l e a r l y they did not allow Tnanas e t al. (16) t o d e t e c t CFP, for t m basic reasons: ( a ) t h e i r use of n o n s i e v i s s , *ich f a i l e d t o retard IgGCFP canplexes and probably inhibited the r e ease of the CFP b a n IgC (24), and ( b ) t h e i r use of 1.0 t o 1.2'1 Ampholine(~\ c a r r i e r amphol y t e s i n t h e i r modified method ( a concentration of 2.0 t o 3.02 is necessary f o r proper focusing of t h e CFP).
Tully e t (17) mention two other important points. First, they emphasize t h e f a c t t h a t the protein banding pattern i n t h e upper few millimeters of an individual CFP-positive sample may vary s e w h a t . Second, they strongly f e e l t h a t known positive and negative controls oarst be used t o a s s i s t i n the i n t e r p r e t a t i o n of specimens being screened. I agree with the f i r s t p i n t and offer Figure 1 a s further evidence f o r t h i s point. Figure 1 shows the patterns fran tw CF patients.
Each sample presents a Unique pattern i n the u p p e m t centimeter of the p r o f i l e , yet both a r e CFP positive and d i s t i n c t l y d i f f e r e n t fran the normal controls ( a l l samples bere analyzed using an amount of s e m containing 300 ug I@). I a l s o agree with t h e second point and m u l d be happy t o collaborate i n an investigation t o determine whether lyophilized s e r a might be usable a s standards.
Lyophilized samples may be s t a b l e a s pertains t o prevention of the destruction o f CFP, and i n theory the sample could be shipped f r m anywhere i n the uorld t o my laboratory ( o r others) t o be screened.
Recent research i n t h i s laboratory, however, indicates t h a t there is a simpler way t o s t a b i l i z e the sample and ensure t h a t CFP, i f present, is not degraded.
Previously. he showed t h a t protein A conjugated t o Sepharose a-kB could be used t o remove CF c i l i a r y dyskinesia f a c t o r s (CDF) f r a n any biological fluid containing I& ( o r a s t r u c t u r a l homolog of I&).
IgG can of course be added t o fluids which do not normally contain it. CF-CDF a r e believed t o bind t o IgG (25). Aa part of our continuing e f f o r t s t o characterize the CFP b~ have recently determined t h a t incubation of s e r a with protein A -Sepharose CL-48 removes the CFP along with IgG (18) .
Examples of the banding p r o f i l e s obtained for sera before and a f t e r incubation with protein A a r e shown i n Figure 1 , a s a r e examples of p r o f i l e s of the material released fran t h e protein A gel i t s e l f . The removal of t h e CFP-IgG canplex using protein A s t a b i l i z e s CFP, since when the Sepharose gel is bashed with buffer o r s a l i n e enzyms a r e removed which might otherwise i n a c t i v a t e CFP (27). In addition, t h e amount of IgC can be quantitated, a s the binding capacity of protein A f o r IgG is known (25); t h i s will undoubtedly be of value i n the mintenance of StandaPdized conditions f o r screening.
A Canmittee of t h e National Research
o r ; and ( e ) ensure t h a t processing and delivery of the sample w i l l not cmpranise the v a l i d i t y of the t e s t through significant a l t e r a t i o n of the properties of the sample.
It is my feeling t h a t with the recent confirmations of our r e s u l t s , the IEF assay which ve have developed now meets c r i t e r i a ( a ) through (d) .
N o other assay system currently available can detect c a r r i e r s of the CF gene a s e f f i c i e n t l y .
In addition, assming t h a t e i t h e r lyophilization or adsorption of the sample with protein A -Sepharose CL-4B can be used t o preserve the s t r u c t u r a l i n t e g r i t y of the CFP, then c r i t e r i o n ( e ) can e a s i l y be achieved. l h e use of protein A o f f e r s a simple bay t o ensure that the v a l i d i t y of the t e s t is not cmprcmised through s i g n i f i c a n t a l t e r a t i o n s i n the biological ( o r , more important f o r IEF, the physicochmical) properties of the marker used for detection, while allowing for the shipment of e i t h e r standards o r samples t o be screened. Most labora t o r i e s have centrifuges, and the amount of protein A needed per sample m u l d not m k e the cost for its use prohibitive.
Men a substance has been shown t o be a marker f o r c a r r i e r s of a particular disease, c e r t a i n questions immediately a r i s e . h a n g the questions which should be asked are:
( a ) Can the m r k e r be used f o r antenatal detection of fetuses which harbor the defective gene? (b) Can the m r k e r be used, i n canbination with others i f necessary, t o distinguish the hanozygous f r m the h e t e r a v~o u s s t a t e ? ( c ) Since the m r k e r is found i n c a r r i e r s and n o t normal unaffkrted i n d i~i d u~l s , and thus probably is related t o the basic defect resp3nsible for t h e disease, *hat inforoation concerning the basic nature of the gene defect can we gain fran knowledge about t h i s marker o r fran its metabolic relationship t o other known abnormalities associated with t h e disease manifested i n vivo i n the proband o r l n i n v i t r o s t u d i e s using c e l l s f r m t h e proband o r c a r r i e r ?
To begin t o address these questions properly one must have scme conception of the relationship of the marker ( i n t h i s case CFP) t o t h e h o r n characterstics of the disease. Figure 2 presents a scheme which attempts t o l i n k together what a r e , i n t h i s a u t t n r ' s conception, t h e more important c l i n i c a l , biochemical, and pathophysiological findings i n c y s t i c fibrosis.
In t h i s scheme a defect i n t h e a l p h a~n a c r o g l o b u l i n (A2M) synthesized by individuals uho harbor the CF gene is considered t o be a primary defect, and abnormal regulation of the a c t i v i t y of c e r t a i n s e r i n e , t h i o l , o r carboxyl proteases by A2M is f e l t t o be responsible f o r the presence of increased amounts of CFP and other biologi c a l l y a c t i v e substances i n t h e body f l u i d s (such a s C3a o r C b ) (22,23). Alterations i n the a c t i v i t y of these enzymes can lead t o the other changes noted (see additional explanatory s t a t e m n t s i n the legend of Figure 2) . Certain c l i n i c a l problems a r e f e l t t o occur by more than one mechanism. For example, t h e hallmark of t h e disease, namely, an a b n o m l e l e c t r o l y t e canposition of the secretory fluids found in p a t i e n t s with CF, is envisioned t o r e s u l t fran a t l e a s t tu, mechanisms:
( a ) by t h e d i r e c t action of CF factors on ion transport, and (b) through disruptions i n stimulus-coupled secretion o r reabsorption of e l e c t r o l y t e s by t h e exocrine glands due t o an a l t e r a t i o n i n membrane receptors (Figure 2). The p o s s i b i l i t y t h a t CFP o r the CF-CDA (25) can have a d i r e c t e f f e c t on ion transport is derived fran t h e f a c t t h a t these substances a r e polycations and fran documentation t h a t polycations can mimic t h e e f f e c t s produced by hornones, a s they can stimulate o r i n h i b i t adenylate cyclase depending on t h e i r concentration (28). In addition, a d i r e c t defect on A~M-enzym regulation could lead t o a t h i r d mechanism f o r abnormal e l e c t r o l y t e l e v e l s , involving the defective m t a b o l i m of a hypothetical f a c t o r called "kinin-E" (3).
tRnn and Blau have proposed t h a t kinin-E i n i t i a t e s ion reabsorption i n exocrine glands (31, and t h a t it is m i s s i w o r decreased i n the proximal ducts of CF glands, due t o a deficiency i n an arginine esterase a c t i v i t y believed t o a c t i v a t e Lcinin-E (3). Obviously, i n my scheme, A$ would be responsible for controlling t h e arginine esterase.
The impact of defective A2M-enzyme interactions on the disease process is probably exacerbated by the f a c t t h a t another major protease i n h i b i t o r , namely, alpha-l-antitrypsin, may t r a n s f e r inhibited proteases such a s trypsin o r e l a s t a s e t o A2M (9) . Ihus, i n CF c e r t a i n proteases would be canpletely immune t o regulation, especially during acute o r chronic illnesses.
Certain secondary defects such a s a l t e r a t i o n s i n membrane receptors o r i n glycosyltransferase a c t i v i t y a r e envisioned t o e s c a l a t e the disruption i n haneostatic mechanism i n i t i a l l y caused by t h e defective A2M-enzyme interactions.
It is possible, f o r example, t h a t the a l t e r a t i o n s i n glycosyltransferase a c t i v i t y noted by Rao e t (10) and Louisot e t (6) could lead t o changes i n t h e carbohydrate portion of c e r t a i n enzymes o r of A2M i t s e l f and thus a f f e c t t h e i r binding properties (1 ).
A correlation between defective ApM-enzyme interactions and the neneration of CF-CDA and CFP is especially a p w r e n t when one examines c e l l s i n c u l t u r e (20).
For example, the i n vit& generation of CF-CDA by CF o r c a r r i e r c e l l s has been shorn p r i m a r i l y c e l l types which i n the normal individual a r e a l s o capable of the synthesis and secretion of A2M. This is true for both peripheral blood leukocytes (4) (mnocytes) and-f i b r o b l a s t s (7). Fibroblast cultures i n p a r t i c u l a r have been used i n several studies on the c e l l u l a r m t a b o l i m of CF f a c t o r s (21, and I have recently found t h a t CF mnocytes may s e c r e t e a t l e a s t two CDAs (20), which were shown previously t o be present i n cell-free supernatants P a n CF o r c a r r i e r peripheral blood leukocyte and long-term lymphoid c e l l cultures (25).
The f a c t t h a t A2M and CF-CDA a r e m d e by f i b r o b l a s t s and monocytes points t o t h e f a c t t h a t these m r k e r s and t h e CFP w i l l be of value for t h e detection of the CF gene antenatally. Screening f o r CFP and CF-CDA by IEF o r radioinnnunoassay i n conjugation with quantitation of the functional capacity of A2M could distinguish a f e t u s h m z y g o u s fran one heterozygous f o r the CF gene, since c a r r i e r s s h w only a p a r t i a l defect i n A2M regardless of whether IEF (22) o r other methods (12,13) a r e used.
As part of the ongoing research i n my laboratory, I aa u t i l i z i n g purified peripheral blood monocytes o r pulmonary macrophages a s isolated model systems t o study the possible r o l e of a defective A2M i n the generation o r accumulation of CDAs and the r o l e of t h e A2M-CDA metabolic i n t e r r e l a t i o n s h i p i n the disease process ( p a r t i c u l a r l y pulnwnary disease). I hope t h a t the above-related s t u d i e s i n CF will define more c l e a r l y and strengthen the concepts presented i n Figure 2 . Scheme r e l a t i n g what seem t o be t h e most important c l i n i c a l , biochemical, and pathophysiological findings i n CF. Dotted l i n e s denote "feedback loops".
Normally these connections serve t o escalate disruptions in homeostatic mechanism i n i t i a l l y caused by some other more fundamental abnormality i n metabolim. Double-headed arrows show interrelationships ere i n c e r t a i n instances it may be d i f f i c u l t to separate cause and e f f e c t .
One important aspect of the disease not accounted for i n the diagram is t h e problen of s t e r i l i t y . In males t h i s could involve the pathway shorn on the extrane r i g h t ( a l t e r a t i o n s i n the quantity o r q u a l i t y of membrane receptors) , leading u l t i o a t e l y i n most cases t o a f a i l u r e of the b l f f i a n duct to develop properly during e a r l y f e t a l l i f e , due t o a lack of proper signals for i n d w t i o n of development.
In females there a r e multiple reasons for s t e r i l i t y (30).
